Current Report Filing (8-k)
August 08 2022 - 04:12PM
Edgar (US Regulatory)
0001812173 false 0001812173 2022-08-08
2022-08-08 0001812173
RBOT:ClassCommonStockParValue0.0001PerShareMember 2022-08-08
2022-08-08 0001812173
RBOT:WarrantsToPurchaseOneShareOfClassCommonStockEachAtExercisePriceOf11.50PerShareMember
2022-08-08 2022-08-08 iso4217:USD xbrli:shares iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported):
August 8, 2022
VICARIOUS SURGICAL INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-39384 |
|
87-2678169 |
(State
or other jurisdiction of
incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
78 Fourth Avenue |
|
|
|
|
Waltham,
Massachusetts |
|
|
|
02451 |
(Address of principal executive
offices) |
|
|
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (617)
868-1700
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ |
Written
communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
☐ |
Soliciting
material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
☐ |
Pre-commencement
communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
☐ |
Pre-commencement
communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on
which registered |
Class A common stock, par value $0.0001 per
share |
|
RBOT |
|
The New York Stock Exchange |
Warrants to purchase one share of Class A common stock, each at an
exercise price of $11.50 per share |
|
RBOT WS |
|
The New York Stock Exchange |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company ☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
Item
2.02. |
Results
of Operations and Financial Condition. |
On
August 8, 2022, Vicarious Surgical Inc. (the “Company”) issued a
press release announcing its results for the second quarter ended
June 30, 2022 and providing a business update. A copy of the press
release is furnished as Exhibit 99.1 hereto.
The
information in this Current Report on Form 8-K (including Exhibit
99.1) shall not be deemed to be “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a
filing.
Item
9.01 |
Financial
Statements and Exhibits. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
VICARIOUS
SURGICAL INC. |
|
|
|
|
By: |
/s/Adam
Sachs |
|
Name: |
Adam
Sachs |
|
Title: |
President
and Chief Executive Officer |
2
D8 (NYSE:DEH)
Historical Stock Chart
From Dec 2022 to Jan 2023
D8 (NYSE:DEH)
Historical Stock Chart
From Jan 2022 to Jan 2023